VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - April 12, 2007) - Urodynamix Technologies Ltd. (TSX VENTURE:URO) announced that it has received notification from Health Canada allowing the Company to expand its clinical trial (“NIRS IAP Study”) at the Foothills Medical Centre in Calgary, Alberta. Under the approved protocol the Company may enroll up to 70 intensive care unit (“ICU”) patients and will monitor subjects continuously for up to 7 days.
